Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Group A, group B and group C meningococcus combined vaccine and preparation method thereof

A meningococcal and combined vaccine technology, applied in bacteria, antibacterial drugs, pharmaceutical formulations, etc., can solve problems such as hidden safety hazards of vaccines, reversal of toxicity of protein carriers, etc., and achieves broad targeting, good specificity, and good specificity Effect

Active Publication Date: 2014-08-27
CHENGDU OLYMVAX BIOPHARM
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, no trace of formaldehyde or glutaraldehyde is added to the conjugate vaccine with TT or DT as the protein carrier, so there is a risk of reversal of the toxicity of the protein carrier
And tetanus toxoid is a highly allergenic substance, although the detoxified tetanus toxoid (TT) also has a high risk of allergies
These factors all constitute a safety hazard of vaccination

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Group A, group B and group C meningococcus combined vaccine and preparation method thereof
  • Group A, group B and group C meningococcus combined vaccine and preparation method thereof
  • Group A, group B and group C meningococcus combined vaccine and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1AB

[0033] Embodiment 1ABC group meningococcal combined vaccine and its preparation process

[0034] This example is composed of purified component antigens from four strains of meningococcus, and the specific serogroups and antigenic components are as follows:

[0035] Group A meningococcal strains were obtained from China Medical Bacteria Collection Center (CMCC), strain number CMCC29201, and the component antigen was capsular polysaccharide (CPS).

[0036] Group C meningococcal strains were obtained from China Medical Bacteria Collection Center (CMCC), strain number CMCC29205, and the component antigen was capsular polysaccharide (CPS).

[0037] Group B meningococcal strains are from China Medical Bacteria Collection Center (CMCC), strain number CMCC29356, and the component antigen is outer membrane protein vesicle (OMV).

[0038] The group B meningococcal strain is derived from the isolated strain xrsw341215 from the blood samples of domestic group B meningococcal meningitis ...

Embodiment 2

[0054] Example 2 Comparison of Immunogenicity of Group AC Meningococcal Conjugate Vaccines from Different Manufacturers

[0055] Experimental program:

[0056] 1. Vaccines from four sources are domestic 1AC vaccine, domestic 2AC vaccine, Xiangrui biological AC vaccine and the ABC group meningococcal combined vaccine prepared in Example 1.

[0057] 2. Experimental animals: BALB / C mice, 12-14 grams / body weight.

[0058] 3. Grouping: 10 mice in each group, half female and half male, and 5 mice of the same sex were raised in each tank.

[0059] 4. Immunization method: subcutaneous injection; immunization dose: 2.5 μg polysaccharide / groups A and C.

[0060] 5. Immunization procedure: three injections in the whole process, that is, one injection each on day 0, 14, and 21.

[0061] 6. Serum separation and detection: Blood was collected two weeks after each immunization, serum was separated, antibody titer of a single mouse was determined by ELISA, geometric mean titer (GMT) of eac...

Embodiment 3

[0067] Example 3 Determination of the cross-antibody between the immune serum of xrsw341215 isolated from domestic group B meningococcal meningitis patients and dominant pathogenic group B meningococcal meningitis strains from different sources at home and abroad

[0068] 1. Domestic strains: Screened from 167 domestically collected ECM patients and carriers of group B, and identified 8 dominant strains in total (Table 2).

[0069] Table 2 Domestic isolates of group B patients

[0070]

[0071]

[0072] 2. Foreign strains: respectively from the US FDA, the Netherlands National Institute of Public Health and Environmental Protection, and China National Institute for Food and Drug Control. (table 3)

[0073] Table 3 Strains collected abroad

[0074]

[0075] 3. Preparation of immune serum of xrsw341215 strain

[0076] Animals: SPF grade N1H mice, 10 / group, 12-14 grams.

[0077] Preparation of immune stock solution: Kaikai working seed batch 1 strain, inoculated in s...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a group A, group B and group C meningococcus combined vaccine which is composed of polysaccharide-protein conjugates and a group B ST-4821 genotype (xrsw341215) meningococcus outer membrane protein vesicle (OMV), wherein the polysaccharide-protein conjugates are obtained in a manner that a group A meningococcus capsular polysaccharide and a group C meningococcus capsular polysaccharide are each subjected to covalent binding with a group B serotype 4-type (CMCC29356) meningococcus outer membrane protein vesicle (OMV). The vaccine can simultaneously prevent group A, group B and group C meningococcus invasive diseases, has better protective effects especially on prevention aiming at epidemic cerebrospinal meningitis high-risk groups at the age of less than 2 years, and moreover, has better specificity and better protection effect aiming at nature group A, group B and group C meningococcus invasion.

Description

technical field [0001] The invention relates to a multivalent combined vaccine composed of multiple serogroup meningococcal vaccines and its preparation process, in particular to a combined vaccine composed of ABC group meningococcal polysaccharide conjugates and protein antigen components and its preparation method. Background technique [0002] Invasive sepsis, meningitis, pneumonia and other diseases caused by meningococcal infection occur all over the world, causing high mortality and disability, and seriously threatening human health. According to the differences in the composition of meningococcal capsular polysaccharides, it can be divided into 13 serogroups, and all serogroups are pathogenic. Among them, group A, B and C cases are the most, accounting for more than 90% of meningococcal cases. [0003] At present, a variety of meningococcal vaccines of different types and combinations have been marketed at home and abroad, among which capsular polysaccharide vaccine...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/116A61P31/04C12N1/20A61K39/095
Inventor 王建华
Owner CHENGDU OLYMVAX BIOPHARM
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com